Pharmacodynamic model of the dynamic response of Pseudomonas aeruginosa biofilms to drug treatments

Swarnima Roychowdhury,Charles M Roth
DOI: https://doi.org/10.1101/2022.07.29.501971
2022-08-01
bioRxiv
Abstract:Chronic infection by gram-negative bacteria such as Pseudomonas aeruginosa is a leading cause of morbidity and mortality in cystic fibrosis patients in whom overabundant mucus and the formation of bacterial biofilms pose barriers to drug delivery and effectiveness. Accurate pharmacokinetic-pharmacodynamic (PK-PD) models of biofilm treatment could be used to guide formulation and administration strategies to better control bacterial lung infections. To this end, we have developed a detailed pharmacodynamic model of P. aeruginosa treatment with the front-line antibiotics, tobramycin and colistin, and validated it on a detailed dataset of killing dynamics. A compartmental model structure was developed in which the key features are diffusion of drug through a boundary layer to the bacteria, concentration dependent interactions with bacteria, and passage of the bacteria through successive transit states before death. The number of transit states employed was greater for tobramycin, which is a ribosomal inhibitor, than for colistin, which disrupts bacterial membranes. For both drugs, the experimentally observed delay in killing of bacteria following drug exposure was replicated and was consistent with the diffusion time, though for tobramycin, there was an additional delay reflected in the model by passage through the transit states. For each drug, the PD model with a single set of parameters described data across a ten-fold range of concentrations and for both continuous and transient exposure protocols. Furthermore, the parameters fit for each drug individually were used to model the response of biofilms to combined treatment with tobramycin and colistin. The ability to predict drug response over a range of administration protocols allows this PD model to be integrated with PK descriptions to describe in vivo antibiotic response dynamics and to predict drug delivery strategies for improved control of bacterial lung infections.
What problem does this paper attempt to address?